Addressing the Cost vs. Quality Conundrum: 3EO Health Receives FDA Emergency Use Authorization, Launches Groundbreaking Point of Care Technology
- 3EO’s novel technology enables up to 70% savings versus existing point of care molecular tests.
- Demonstrated strong clinical performance of 95% PPA and 100% NPA.
- Delivers enhanced ease-of-use via a preparation-free workflow.
BOSTON–(BUSINESS WIRE)–3EO Health, a “Point of Life” diagnostics company focused on the development of high-performing low-cost molecular diagnostics for both point of care and at-home testing announced today the receipt of an emergency use authorization (EUA) for its SARS-CoV-2 molecular test.
